GLP-1 drugs linked to fewer psychiatric hospital stays in schizophrenia with diabetes
☕ Includes a question for the family ↓
GLP-1 drugs (Ozempic, Wegovy, Mounjaro)Part of a story we are following · 4 articles · See every update
If someone you love lives with schizophrenia and type 2 diabetes, here is good news. A large US study found that adults who started GLP-1 drugs, the medicines used for blood sugar and weight, had fewer psychiatric hospital stays and fewer psychiatric emergency visits.
That means a medicine many people already take for their diabetes may bring a helpful extra. And it was true no matter which comparison the researchers used.
How the study worked
Researchers looked at electronic health records from a large group of US adults with schizophrenia and type 2 diabetes, tracking each person for up to 2 years. They compared people who started a GLP-1 drug with people who started two other kinds of diabetes medicine, and with people who started none of these. The study was published in November 2026 in The Lancet Psychiatry. It is a records study, so it shows a link and can’t prove the drug caused the benefit.
What they found
Of the adults in the study, 9,093 started a GLP-1 drug. Those people were less likely to be hospitalized for psychiatric reasons than people who started no new drug.
They also went to the emergency department for psychiatric reasons less often than people who started none of these drugs.
The benefit showed up against other diabetes medicines too. Compared with people who started a DPP-4 inhibitor (4,968 people) or an SGLT2 inhibitor (5,328 people), the GLP-1 group had fewer hospital stays and fewer emergency visits.
| GLP-1 start compared with | Fewer psychiatric hospital stays | Fewer psychiatric emergency visits |
|---|---|---|
| Starting no new drug | Yes | Yes |
| Starting a DPP-4 inhibitor | Yes | Yes |
| Starting an SGLT2 inhibitor | Yes | Yes |
That matters because comparing with other diabetes drugs shows the result isn’t just about getting any treatment at all.
What is a GLP-1 drug?
GLP-1 receptor agonists copy a hormone your gut makes after you eat. Semaglutide is one well-known example. They lower blood sugar and help with weight, and now researchers are curious about what they do in the brain.
People with schizophrenia often face higher rates of diabetes and weight gain, partly because of antipsychotic medicines. So a diabetes drug that may also support mental health stability fits a real need.
What you can do today
If you or a family member has schizophrenia and type 2 diabetes, bring up metabolic care at the next appointment. Ask whether a GLP-1 drug is a good fit for blood sugar and weight. Keep taking every current medicine as prescribed, and let the prescriber guide any changes.
Talk about it at home
Some medicines made for one job turn out to help in another way too. Scientists notice this when they look at what happens to lots of people over time.
Question for the table
How could scientists check whether the medicine itself is making the difference, and not something else about the people who take it?
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Questions and answers
- What are GLP-1 drugs?
- They are medicines, such as semaglutide, that copy a gut hormone. They are used to lower blood sugar and help with weight.
- What did the study find?
- Adults with schizophrenia and type 2 diabetes who started a GLP-1 drug had fewer psychiatric hospital stays and emergency visits.
- Does this mean GLP-1 drugs treat schizophrenia?
- Not yet. The study shows a link, and future trials will test whether the drugs treat psychiatric symptoms directly.
- Should I change my medicines?
- No. Keep taking what you are prescribed and talk with your prescriber about whether a GLP-1 drug fits your care.
